Krystal Biotech Inc (KRYS)
Quick ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 358,328 | 161,900 | 341,246 | 268,269 | 187,514 |
| Short-term investments | US$ in thousands | 173,872 | 217,300 | 96,854 | 3,031 | 6,186 |
| Receivables | US$ in thousands | 42,040 | — | — | — | — |
| Total current liabilities | US$ in thousands | 33,094 | 28,847 | 25,736 | 15,452 | 3,327 |
| Quick ratio | 17.35 | 13.15 | 17.02 | 17.56 | 58.22 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($358,328K
+ $173,872K
+ $42,040K)
÷ $33,094K
= 17.35
The quick ratio of Krystal Biotech Inc has shown a fluctuating trend over the past five years. The ratio stood at 58.22 in 2019, reflecting a very high level of liquidity, which then decreased to 17.56 in 2020. Subsequently, the ratio increased to 17.02 in 2021, followed by a slight uptick to 13.15 in 2022. Finally, as of December 31, 2023, the quick ratio improved significantly to 17.35.
Overall, the quick ratio indicates the company's ability to meet its short-term obligations with its most liquid assets. The current ratio above 1 suggests that Krystal Biotech Inc is capable of covering its current liabilities with its quick assets. However, the fluctuating nature of the ratio warrants further investigation into the company's liquidity management practices and any underlying factors contributing to these fluctuations.
Peer comparison
Dec 31, 2023